How to Read Japan's NHI Drug Price List (薬価基準): A Guide for Market Access Teams
A practical guide to Japan's NHI drug price list (薬価基準) — how listings are structured, how prices are set, and how revisions work.
Read more →Japan Drug Pricing
Analysis of Japan NHI pricing for global pharma market access teams.
A practical guide to Japan's NHI drug price list (薬価基準) — how listings are structured, how prices are set, and how revisions work.
Read more →How Japan's YJ codes and therapeutic category numbers work, and why mapping them to WHO ATC codes trips up global pharma pricing teams.
Read more →Learn how Chuikyo, Japan's Central Social Insurance Medical Council, shapes NHI drug pricing, revisions, and listings for pharma market access teams.
Read more →How Japan's NHI pricing rules, biennial revisions, and G1 repricing shape hypertension drug prices and generic erosion for global pharma teams.
Read more →How Japan's NHI price revisions, stable-supply rules, and new AMR pull incentives shape antibiotic pricing and launch risk for pharma teams.
Read more →Japan's NHI antibiotic prices are among the lowest on the formulary, yet AMR policy is reshaping prescribing incentives and creating new opportunity for novel agents.
Read more →Japan's NHI covers a broad range of psychiatric drugs, but G1 repricing, CEA scrutiny, and rising diagnosis rates are reshaping the mental health drug pricing landscape.
Read more →Annual NHI price cuts, drug lag, and the US MFN rule are reshaping how foreign pharma companies approach Japan. Here is the current state of market access challenges.
Read more →Japan's NHI drug price revision — once biennial, now annual — closes gaps between listed and actual transaction prices. Here is how the process works and what changed.
Read more →Japan's NHI prices fixed-dose combinations by summing components then applying usefulness premiums or convenience deductions. Here is how the rules work in practice.
Read more →Japan's NHI grants orphan drugs usefulness, innovation, and SAKIGAKE premiums of 5–60%. Learn how the post-2018 framework works in practice for market access teams.
Read more →Japan's formal cost-effectiveness evaluation (CEA) system layers ICER-based price adjustments on top of the existing NHI pricing framework — with scope expanding under FY2026 reforms. Here's what pharma market access teams need to plan for before NHI listing.
Read more →Japan's NHI covers diabetes drugs across DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — but tight restrictions, Market Expansion Repricing risk, and annual price revisions shape the real revenue picture. Here's what pharma market access teams need to understand.
Read more →Japan's NHI oncology pricing combines comparator-based methodology, foreign reference pricing, Market Expansion Repricing risk, and evolving cost-effectiveness rules. This guide explains what pharma market access teams need to know to model Japan cancer drug revenue accurately.
Read more →Japan's SAKIGAKE designation offers pharmaceutical companies a 10–20% NHI pricing premium and expedited review for innovative therapies. Learn how this system—and the newer Rapid Introduction Premium—shapes launch sequencing and pricing strategy for global market access teams.
Read more →Japan's April 2026 NHI drug price revision cut prices 4.02% on a spending basis. Here's what changed structurally and which drugs were hit hardest.
Read more →Japan revises NHI drug prices every April. Here is how the MHLW revision cycle works, what drives price cuts, and what global market access teams need to track.
Read more →